Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. Winer EP, et al. Among authors: ingle jn. J Clin Oncol. 2002 Aug 1;20(15):3317-27. doi: 10.1200/JCO.2002.06.020. J Clin Oncol. 2002. PMID: 12149306 Review.
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. Winer EP, et al. Among authors: ingle jn. J Clin Oncol. 2003 Jul 1;21(13):2597-9. doi: 10.1200/JCO.2003.04.596. Epub 2003 May 5. J Clin Oncol. 2003. PMID: 12732612 No abstract available.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. Winer EP, et al. Among authors: ingle jn. J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review.
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Come SE, et al. Among authors: ingle jn. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):997s-1000s. doi: 10.1158/1078-0432.CCR-05-2268. Clin Cancer Res. 2006. PMID: 16467115 No abstract available.
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Ingle JN, et al. Breast Cancer Res Treat. 2006 Jul;98(2):217-22. doi: 10.1007/s10549-005-9152-1. Epub 2006 Mar 15. Breast Cancer Res Treat. 2006. PMID: 16538529 Clinical Trial.
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. Goetz MP, et al. Among authors: ingle jn. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7. doi: 10.1158/1078-0432.CCR-05-1263. Clin Cancer Res. 2006. PMID: 16609019 Clinical Trial.
427 results